Teva Pharmaceutical Industries Limited (TEVA) reported that its first-quarter net income attributable to the company decreased to $630 million or $0.74 per share, from $859 million or $0.97 per share in the same quarter last year.
The company had net non-GAAP charges of $330 million in the latest-quarter.
Non-GAAP net income attributable to the company also declined to $960 million or $1.12 per share, from $1.30 billion or $1.47 per share in the same quarter last year. Analysts polled by Thomson Reuters expected the company to report earnings of $1.10 per share for the quarter. Analysts' estimates typically exclude special items.
Net revenues for the quarter declined to $4.90 billion from $5.10 billion in the prior year quarter. Twenty analysts had consensus revenue estimate of $4.85 billion for the quarter.
Net revenues in the United States in the first quarter were $2.4 billion , a decrease of 11% compared to the first quarter of 2012, driven primarily by the decline in Provigil sales due to generic competition that began in the second quarter of 2012. In addition, the first quarter of 2012 had significant launches including the generic version of Zyprexa and agreement with Ranbaxy relating to its launch of generic Lipitor. This decrease was partially offset by strong revenues from Copaxone, Treanda, Azilect and our respiratory products, and from other generic products that were not sold in the first quarter of 2012.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.